Evidence map›Paper›PMID 36950736›Full record

ReviewMolecular therapy : the journal of the American Society of Gene Therapy2023

Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.

Zohreh Najminejad, Fatemeh Dehghani, Yousef Mirzaei, Ali Hussein Mer, Seyyed Amirreza Saghi, Mohadeseh Haji Abdolvahab, Nader Bagheri, Anna Meyfour, Ameneh Jafari, Saeed Jahandideh and 6 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. A review of targeted drug delivery with antibody-drug complexes.The Journal of pharmacology and experimental therapeutics · 2025
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. An Antibody-Drug Conjugate for Multiple Myeloma Prepared by Multi-Arm Linkers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 3 countries.

Zohreh NajminejadDepartment of Internal Medicine, School of Medicine, Kerman University of Medical Sciences, Kerman 7616913355, Iran.
Fatemeh DehghaniStudent Research Committee, Larestan University of Medical Sciences, Larestan 7431895639, Iran.
Yousef MirzaeiDepartment of Medical Biochemical Analysis, Cihan University-Erbil, Kurdistan Region, Erbil 44001, Iraq.
Ali Hussein MerDepartment of Nursing, Mergasour Technical Institute, Erbil Polytechnic University, Erbil 44001, Iraq.
Seyyed Amirreza SaghiStudent Research Committee, Larestan University of Medical Sciences, Larestan 7431895639, Iran.
Mohadeseh Haji AbdolvahabRecombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran 1517964311, Iran.
Nader BagheriCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord 8813733450, Iran.
Anna MeyfourBasic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran.
Ameneh JafariATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran 1517964311, Iran.
Saeed JahandidehDepartment of Research and Development, Orchidgene co, Tehran 1387837584, Iran.
Tohid GharibiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 5165665931, Iran.
Zahra AmirkhaniStudent Research Committee, Larestan University of Medical Sciences, Larestan 7431895639, Iran.
Hamed DelamStudent Research Committee, Larestan University of Medical Sciences, Larestan 7431895639, Iran.
Noushin MashatanGraduated, School of Applied Sciences, University of Brighton, Brighton BN2 4GJ, UK. Electronic address: n.mashatan1@uni.brighton.ac.uk.
Hosein ShahsavaraniDepartment of Cell and Molecular Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran 1983963113, Iran. Electronic address: hosein.shahsavarani@gmail.com.
Meghdad Abdollahpour-AlitappehCellular and Molecular Biology Research Center, Larestan University of Medical Sciences, Larestan 7431895639, Iran. Electronic address: abdollahpour1983@yahoo.com.
Islamic Azad University, Larestan Branch · IRMotamed Cancer Institute · IRCihan University-Erbil · IQKerman University of Medical Sciences · IRShahid Beheshti University · IRShahid Beheshti University of Medical Sciences · IRShahrekord University of Medical Sciences · IRSulaimani Polytechnic University · IQTabriz University of Medical Sciences · IRUniversity of Brighton · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic small molecules to targeted cancer cells, leading to an enhanced therapeutic index through increased antitumor activity and decreased off-target toxicity. ADCs hold great promise for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after the approval and tremendous success of trastuzumab emtansine and trastuzumab deruxtecan, representing a turning point in both HER2-positive breast cancer treatment and ADC technology. Additionally and importantly, a total of 29 ADC candidates are now being investigated in different stages of clinical development for the treatment of HER2-positive breast cancer. The purpose of this review is to provide an insight into the ADC field in cancer treatment and present a comprehensive overview of ADCs approved or under clinical investigation for the treatment of HER2-positive breast cancer.

Indexed as

Antineoplastic AgentsBreast NeoplasmsImmunoconjugatesAdo-Trastuzumab EmtansineAntibodies, MonoclonalErb-b2 Receptor Tyrosine KinasesFemaleHumansTrastuzumabAdo-Trastuzumab EmtansineAntibodies, MonoclonalAntineoplastic AgentsErb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabADCsantibody-drug conjugatesHER2HER2-postive breast cancerhuman epidermal growth factor receptor 2immunoconjugatestargeted therapy

Identifiers

PMID36950736
PMCPMC10362395
OpenAlexW4353094424

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.